SCHEMBL2163283

SCHEMBL2163283

CC1OCc2sc(NC(=O)c3c(C(F)(F)F)ccc(Cl)c3F)c(C(=O)c3ccccc3)c21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 13/20 0.39
CNR1 P21554 10/20 0.39
RAB7A P51149 2/20 0.38
TP53 P04637 1/20 0.37
ANO1 Q5XXA6 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.35
PLA2G1B P04054 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163131 0.91 CNR2 (0.40) CNR2CNR1RAB7AANO1ALDH1A1
SCHEMBL2162462 0.84 CXCR2 (0.42) CNR2CNR1TP53ALDH1A1MAPT
SCHEMBL2162083 0.83 CNR1 (0.59) CNR2CNR1
SCHEMBL2162079 0.81 CNR2 (0.56) CNR2CNR1
SCHEMBL2162342 0.79 CNR2 (0.52) CNR2CNR1RAB7AALDH1A1MAPT
SCHEMBL2162337 0.76 CNR2 (0.54) CNR2CNR1RAB7AALDH1A1MAPT
SCHEMBL2162084 0.76 ANO1 (0.54) CNR2CNR1ANO1MEN1KMT2A
SCHEMBL2162097 0.76 CNR2 (0.47) CNR2CNR1TP53ANO1ALDH1A1
SCHEMBL2162613 0.75 CNR2 (0.51) CNR2CNR1
SCHEMBL2163620 0.74 RAB7A (0.42) CNR2CNR1RAB7ATP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US claimed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US claimed
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US disclosed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US disclosed
WO-2008028094-A1 COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, OPRL1 CNR2 2/4885CNR1 1/4885RAB7A 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.